Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - CBRNE - Venezuelan Equine Encephalitis : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Dengue Fever

Encephalitis

Influenza

Malaria

Meningitis

Yellow Fever




Patient Education
Bioterrorism and Warfare Center

Brain and Nervous System Center

Biological Warfare

Personal Protective Equipment

Encephalitis Overview




Author: Robert Derlet, MD, Professor of Emergency Medicine, University of California at Davis School of Medicine; Chief Emeritus, Emergency Department, University of California at Davis Health System

Robert Derlet is a member of the following medical societies: American Academy of Emergency Medicine, American Association for the Advancement of Science, Infectious Diseases Society of America, Society for Academic Emergency Medicine, and Wilderness Medical Society

Editors: Jerry L Mothershead, MD, Medical Readiness Consultant, Medical Readiness and Response Group, Battelle Memorial Institute; Advisor, Technical Advisory Committee, Emergency Management Strategic Healthcare Group, Veteran's Health Administration; Adjunct Associate Professor, Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Author and Editor Disclosure

Synonyms and related keywords: Venezuelan equine encephalitis, VEE, encephalitis, equine encephalomyelitis, Togaviridae, Alphavirus, mosquito-borne virus, mosquito-borne viral disease, biological weapons, biological warfare, viral encephalitis

Background

Venezuelan equine encephalitis (VEE) is a mosquito-borne viral disease characterized by fever and other symptoms that may include severe headache, back pain, myalgias, prostration, chills, nausea, vomiting, and weakness. The disease may progress to encephalitis and death.

Clinical symptoms are similar to those of many other zoonotic viral infections that cause fever and headache, including St Louis encephalitis, Japanese encephalitis, West Nile encephalitis, and dengue. Unlike these infections, which are caused by a Flavivirus, VEE is caused by an enveloped single-stranded RNA virus of the Togaviridae family, Alphavirus genus.

Alphaviruses include eastern equine encephalitis, western equine encephalitis, Chikungunya fever, Semliki Forest disease, Barmah Forest fever, and Ross River fever. Some species of the Alphavirus genus have characteristics that make them suited for weaponization, a fact that was recognized in the 1930s and 1940s. Alphaviruses could potentially be produced in large quantities and delivered effectively via an aerosol route. Unlike many other pathogenic viruses, these viruses are relatively stable in the environment.

VEE remains a potentially potent biological weapon. If this virus was deployed efficiently, it could incapacitate thousands of people for a week or more and cause untold psychologic stress to millions. VEE is potentially susceptible to genetic manipulation in advanced laboratories. This characteristic has proven useful for researchers aiming to develop more effective vaccines; however, it could also be exploited to produce more effective biological weapons. A live-attenuated VEE vaccine has been used in horses. A formalin-inactivated vaccine has been developed for use in humans, although further investigation of its protective effects is needed.

History of disease

VEE, first recognized in the 1930s, has been responsible for numerous outbreaks of febrile illnesses and encephalitis involving thousands of cases. VEE viruses are transmitted among equines and rodents by a variety of mosquito species.

Human and animal infections have occurred in equatorial South America and Central America, including Colombia, Panama, Peru, Brazil, Venezuela, French Guiana, Guyana, and Surinam. Mortality rates vary in horses but reportedly are as high as 80%. Hundreds of thousands of equines have died in epidemics.

The impact caused by VEE epidemics is best illustrated by examining large Venezuelan and Colombian epidemics that occurred in 1962-63, 1967, and 1995. In the 3 epidemics combined, more than 300,000 humans were infected, with more than 4% experiencing severe neurologic symptoms and more than 2000 (<1%) deaths reported. Clinically apparent but less severe neurologic manifestations occurred in additional patients.

Symptomatic manifestations of disease are variable. The incidence among humans during epidemics has been as high as 300 in 1000 persons per month, especially among children younger than 15 years. In some epidemics, more than 50% of persons residing in rural villages have become ill, while during other outbreaks, the incidence has been less, although minimally infected persons may not have been reported.

Initial diagnosis may be difficult; therefore, a high index of suspicion is required in examining a symptomatic patient with a history of travel to an endemic area or an area experiencing an active epidemic.

For more information, see Medscape's Bioterrorism Resource Center.

Pathophysiology

The VEE RNA is enveloped in an icosahedral coat structure, with a diameter of about 60 nm. Surface spikes are recognized by host receptors, which afford adsorption of the particle into the host cells. Chronologic pathophysiology is described under Virus action below. Thirteen distinct subtypes have currently been identified; however, only subtype I is associated with human disease. Numerous groups exist within this subtype; groups I-A and I-B cause most cases of VEE found in humans.

Zoonotic transmission

Mosquitoes serve as a vector for transmission of VEE. VEE has a zoonotic reservoir in bats, birds, rodents, equines (horses, donkeys, mules), and certain tropical jungle mammals. Rodents and other small animals are the most important amplifiers in endemic preservation of the virus in tropical forests, swamps, and marshlands. Horses are the most important amplifier hosts in large epidemic outbreaks.

Humans and horses are infected by a wide variety of mosquito vectors, including Culex, Mansonia, Psorophora, and Aedes species. The principal vector for humans is Aedes aegypti. Humans acquire infection as an incidental dead-end infection of the normal animal-mosquito-animal cycle in nature. Blood viral loads of infected patients may exceed the threshold level required to infect mosquitoes, and human-mosquito-human transmission has been suspected in some epidemics.

Other potential modes of transmission

The potential for person-to-person transmission exists. VEE virus has been isolated from throat washings of patients. Furthermore, aerosol transmission of the virus has occurred as a result of laboratory accidents or lack of laboratory precautions. An analysis of laboratory incidents suggests that the aerosol form of VEE is highly infectious, making VEE a potential biowarfare agent. This could be especially worrisome if strains are genetically altered to increase pathogenicity.

The Centers for Disease Control and Prevention (CDC) extensively analyzed the 1995 VEE outbreak in northwest Colombia and reported a 5% secondary household attack rate. Whether these secondary attacks were from bites by mosquitoes infected from animals or humans was unclear. At the present time, direct human-to-human transmission is not scientifically proven but is suspected.

Virus action

The virus gains access to a human's bloodstream after he or she is bitten by an infected mosquito. VEE is lipid- and glycoprotein-enveloped; it contains RNA of approximately 12 kilobase pairs in length. The virus initially enters lymphatic and bone marrow cells by receptor-mediated endocytosis. After the virus replicates and releases itself into the bloodstream, it infects other cells, causing fever and the other symptoms typical of febrile illnesses. In a subset of patients, the virus gains entrance into the CNS, where it continues to replicate, resulting in acute encephalitis.

An initial immune response with immunoglobulin M (IgM) occurs specific to viral surface components, followed by neutralizing antibody and other immune defenses against the virus infection. Serologic studies of populations exposed during epidemics have demonstrated a high seroconversion rate, with most persons experiencing only flulike symptoms or no symptoms at all.

Frequency

United States

VEE currently is rare in the United States. A major epidemic in horses occurred in Texas in the past, but fewer than 100 laboratory-confirmed cases in humans are documented. Data from international outbreaks suggest that many more infections occurred that were subclinical or mild. Unless a large-scale epidemic in horses occurs in the United States, VEE observed in US EDs will have been acquired abroad or due to an intentional release of the pathogen. However, changing climatic patterns may favor establishment of the virus in wild rodents in warmer areas of the United States.

International

Endemic areas: The incidence in endemic subtropical and tropical areas has not been clearly determined because isolated cases resulting from rodent-mosquito-human transmission may remain undocumented.

Epidemic areas: Epidemics that occur every few years have demonstrated that equines are highly susceptible to severe disease and respond poorly. Mosquito-exposed humans in these areas are also at risk, and most are believed to become infected; however, most human infection is subclinical or mild.

Mortality/Morbidity

  • The overall mortality rate from epidemics is 0.5-1%. In patients who develop encephalitis, the mortality rate is in the range of 20%.
  • Encephalitis is clinically diagnosed in 2-4% of adults and in 3-5% of children.

Sex

Data regarding sex are nonspecific; however, many ranch workers in at-risk areas are male, thus increasing the risk in males.

Age

Data from epidemics demonstrate that children have the highest risk of acquiring moderate or severe forms of the infection.



History

Symptoms range from infection without symptoms, to a mild flulike illness to severe systemic disease, encephalitis, and death.

  • Patients give a history of exposure to mosquitoes in an area endemic for VEE. Because the incubation period ranges from 1 day to 1 week, a patient who has been exposed in an endemic area may present to a US ED with VEE.
  • Suspect VEE in anyone with a febrile illness who has recently traveled in rural areas of Central America or tropical South America. Consider it in the differential diagnosis whenever considering the diagnosis of dengue in persons coming from those areas.
  • Mild infection: Persons with the mild form of infection may be asymptomatic. Others may develop only minimal flulike symptoms of low-grade fever, myalgias, or headache.
  • Moderate infection: Typical symptoms of moderate disease found on history include fever, intermittent chills, myalgias, back pain, headache, photophobia, vomiting, and/or hypesthesia. Less common complaints include sore throat.
  • Severe infection: Patients with the severe form present with an acute-onset high fever (temperature, 39-40°C), severe myalgias, severe back pain, headache, photophobia, vomiting, weakness, prostration, and confusion.
  • Biological warfare: Suspect biological warfare or terrorism when large numbers of patients present with VEE from a nonendemic region.

Physical

The physical examination results in nonspecific findings of an acute febrile illness. In patients with advanced disease in which encephalitis has developed, findings may include nuchal rigidity and ataxia.

  • Fever
    • May be low grade in patients with mild cases
    • In patients with moderate-to-severe cases, may be 38-40°C
  • Hypotension in dehydrated patients
  • Nuchal rigidity in patients developing encephalitis
  • Altered mental status in moderate and/or severe infections
  • Coma in patients with progressed encephalitis

Causes

VEE is caused by exposure to mosquitoes infected with VEE in endemic or epidemic areas or by intentional release of a VEE biological weapon.

  • Endemic-acquired infections: These are the most difficult infections to diagnose. In many mosquito-infested areas of central and tropical South America, rodents dwelling in the jungle, swamp, marsh, or forest harbor VEE. Because many other infectious agents from these areas also cause febrile illnesses, VEE is not always considered early in the patient's course.
  • Epidemic-acquired infections: These infections are usually well publicized, with public health and veterinary officials containing the infection in a high-visibility manner. Patients with fever originating from these areas may present with worries about VEE and may request that the disease be excluded specifically.



Dengue Fever
Encephalitis
Influenza
Malaria
Meningitis
Yellow Fever

Other Problems to be Considered

St Louis encephalitis
West Nile fever
Japanese encephalitis
Western equine encephalitis
Eastern equine encephalitis
Influenza



Lab Studies

  • In patients presenting to the ED with a febrile illness, perform standard laboratory tests, including a CBC, electrolyte assessment, LFTs, urinalysis, and other tests as indicated by the history and physical examination.
  • The results of most laboratory studies in patients infected with VEE are nonspecific for febrile illnesses. However, a CBC and the LFTs may demonstrate the following:
    • CBC - Lymphopenia and thrombocytopenia
    • LFTs - Elevated lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) levels
  • Send serum to a laboratory with the capacity to measure IgM and immunoglobulin G (IgG) using enzyme-linked immunosorbent assay (ELISA) tests.

Imaging Studies

  • Chest radiography may help exclude other infectious causes of fever such as pneumonia or tuberculosis.
  • MRI may be useful in establishing the diagnosis of encephalitis.

Procedures

  • A lumbar puncture may be performed. Cerebrospinal fluid may demonstrate elevated lymphocytes in patients with encephalitis. Cerebrospinal fluid sent to appropriate laboratories can receive further testing to identity VEE.



Prehospital Care

No specific treatment other than supportive care is available. VEE is an RNA virus; therefore, antivirals that have been successful against DNA viruses are ineffective.

Emergency Department Care

Treatment is symptomatic and in the ED most likely involves correcting fluid deficiencies.

Consultations

Contact an infectious disease specialist if VEE is suggested. In addition, involve the local county health department.



No specific medications are approved for treatment of VEE. In vitro laboratory studies suggest that ribavirin and other nucleoside analogues may be future agents, but they are not used clinically.



Further Inpatient Care

  • Admit patients with possible VEE and observe them for progression to encephalitis.

Transfer

  • In hospitals that do not have infectious disease specialists on staff, consider transferring the patient to a tertiary referral medical center.

Deterrence/Prevention

  • Endemic areas: Protection from mosquito bites is important. Visitors to endemic areas should take appropriate precautions to avoid mosquito bites, including proper clothing, insect repellant, and mosquito nets.
  • Epidemic areas: Persons other than medical teams that are part of a response organized or approved by the local or national governments should avoid visiting areas experiencing ongoing epidemics.
  • Vaccines: A live-attenuated virus can be used to vaccinate equines. A formalin-inactivated virus has been used to vaccinate human laboratory workers at risk, but this vaccine is not available to the general public. Work is continuing to develop a low cost, low side effect vaccine.
  • Biological warfare or terrorism: Healthcare providers must maintain a high index of suspicion for this diagnosis.
  • CDC: Check the CDC Web site before traveling to specific Central American and South American countries to determine if an epidemic is occurring or if special warnings have been issued.

Complications

  • Admit patients with suspected VEE, provide supportive care, and observe them for potential progression to encephalitis. In patients who develop encephalitis, the mortality rate is in the range of 20%. Encephalitis is clinically diagnosed in 2-4% of adults and in 3-5% of children.

Prognosis

  • Recovery from the illness occurs in 99% of adults and in 97-98% of children.

Patient Education



Medical/Legal Pitfalls

  • Preexposure: Failure to warn patients who plan to travel to endemic areas about VEE may place the physician at a small risk.
  • Postexposure: Failure to diagnose VEE may place the physician at a medicolegal risk. However, since no treatment is available and direct human-to-human transmission is debatable, this risk is small. The most common error in the United States may occur from misdiagnosing VEE as influenza in a patient returning from an endemic area.



  • Aguilar PV, Greene IP, Coffey LL. Endemic Venezuelan equine encephalitis in northern Peru. Emerg Infect Dis. May 2004;10(5):880-8. [Medline].
  • Anishchenko M, Bowen RA, Paessler S, et al. Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. Proc Natl Acad Sci U S A. Mar 28 2006;103(13):4994-9. [Medline].
  • Bernstein BJ. The birth of the U.S. biological-warfare program. Sci Am. Jun 1987;256(6):116-21. [Medline].
  • Bowen GS, Fashinell TR, Dean PB, Gregg MB. Clinical aspects of human Venezuelan equine encephalitis in Texas. Bull Pan Am Health Organ. 1976;10(1):46-57. [Medline].
  • Carrara AS, Coffey LL, Aguilar PV, Moncayo AC, Da Rosa AP, Nunes MR. Venezuelan equine encephalitis virus infection of cotton rats. Emerg Infect Dis. Aug 2007;13(8):1158-65. [Medline].
  • CDC. Update: Venezuelan equine encephalitis--Colombia, 1995. MMWR Morb Mortal Wkly Rep. Oct 20 1995;44(41):775-7. [Medline].
  • CDC. Venezuelan equine encephalitis--Colombia, 1995. MMWR Morb Mortal Wkly Rep. Oct 6 1995;44(39):721-4. [Medline].
  • Charles PC, Brown KW, Davis NL, et al. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology. Feb 17 1997;228(2):153-60. [Medline].
  • Charles PC, Walters E, Margolis F, Johnston RE. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology. Apr 20 1995;208(2):662-71. [Medline].
  • Estrada-Franco JG, Navarro-Lopez R, Freier JE, Cordova D, Clements T, Moncayo A. Venezuelan equine encephalitis virus, southern Mexico. Emerg Infect Dis. Dec 2004;10(12):2113-21. [Medline].
  • Hart MK, Caswell-Stephan K, Bakken R, et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine. Jul 1 2000;18(26):3067-75. [Medline].
  • Hoke CH. History of U.S. military contributions to the study of viral encephalitis. Mil Med. Apr 2005;170(4 Suppl):92-105. [Medline].
  • Huxsoll DL, Patrick WC 3rd, Parrott CD. Veterinary services in biological disasters. J Am Vet Med Assoc. Mar 15 1987;190(6):714-22. [Medline].
  • Leon CA. Sequelae of Venezuelan equine encephalitis in humans: a four year follow-up. Int J Epidemiol. Jun 1975;4(2):131-40. [Medline].
  • McClain DJ, Pittman PR, Ramsburg HH, et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis. Mar 1998;177(3):634-41. [Medline].
  • Molina OM, Morales MC, Soto ID, et al. [Venezuelan equine encephalitis. 1995 outbreak: clinical profile of the case with neurologic involvement]. Rev Neurol. Aug 16-31 1999;29(4):296-8. [Medline].
  • Moncayo AC, Medina GM, Kalvatchev Z. Genetic diversity and relationships among Venezuelan equine encephalitis virus field isolates from Colombia and Venezuela. Am J Trop Med Hyg. Dec 2001;65(6):738-46. [Medline].
  • Navarro JC, Medina G, Vasquez C. Postepizootic persistence of Venezuelan equine encephalitis virus, Venezuela. Emerg Infect Dis. Dec 2005;11(12):1907-15. [Medline].
  • Oberste MS, Schmura SM, Weaver SC, Smith JF. Geographic distribution of Venezuelan equine encephalitis virus subtype IE genotypes in Central America and Mexico. Am J Trop Med Hyg. Apr 1999;60(4):630-4. [Medline].
  • Powers AM, Oberste MS, Brault AC, et al. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J Virol. Sep 1997;71(9):6697-705. [Medline].
  • Rivas F, Diaz LA, Cardenas VM, et al. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995. J Infect Dis. Apr 1997;175(4):828-32. [Medline].
  • Romano-Lieber NS, Iversson LB. [Serological survey on arbovirus infection in residents of an ecological reserve]. Rev Saude Publica. Jun 2000;34(3):236-42. [Medline].
  • Scherer WF, Cupp EW, Dziem GM, et al. Mesenteronal infection threshold of an epizootic strain of Venezuelan encephalitis virus in Culex (Melanoconion) taeniopus mosquitoes and its implication to the apparent disappearance of this virus strain from an enzootic habitat in Guatemala. Am J Trop Med Hyg. Sep 1982;31(5):1030-7. [Medline].
  • Walton TE, Grayson MA. Venezuelan equine encephalomyelitis. In: Monath TP, ed. The Arboviruses: Epidemiology and Ecology. Vol 4. 1988:203-231.
  • Weaver SC, Salas R, Rico-Hesse R, et al. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet. Aug 17 1996;348(9025):436-40. [Medline].
  • Zajtchuk R, Bellamy RF. Viral encephalitides. In: The Textbook of Military Medicine Part I: Chemical and Biological Warfare. 1997:561-590.

CBRNE - Venezuelan Equine Encephalitis excerpt

Article Last Updated: Apr 7, 2008